<DOC>
	<DOCNO>NCT00079092</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth malignant glioma stop blood flow tumor . Drugs use chemotherapy , procarbazine , work different way stop tumor cell divide stop grow die . Combining thalidomide procarbazine may kill tumor cell . PURPOSE : This phase II trial study well give thalidomide together procarbazine work treat patient recurrent progressive malignant glioma .</brief_summary>
	<brief_title>Thalidomide Procarbazine Treating Patients With Recurrent Progressive Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient recurrent progressive malignant glioma treat thalidomide procarbazine . Secondary - Determine progression-free survival patient treat regimen . - Determine overall survival patient treat regimen . - Determine quality life patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral procarbazine daily day 1-5 oral thalidomide daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Quality life assess baseline every odd course . Patients follow every 2 month . PROJECTED ACCRUAL : A total 23-55 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Anaplastic mixed oligoastrocytoma Progressive recurrent disease* radiotherapy without chemotherapy NOTE : *Patients prior lowgrade glioma progress therapy find highgrade glioma eligible Measurable disease MRI CT scan PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy More 2 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL Transaminases ≤ 4 time upper limit normal Renal Creatinine ≤ 1.7 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use 1 highly active method 1 additional effective method contraception 1 month , , 4 week study treatment No concurrent serious infection No concurrent medical illness would preclude study treatment No malignancy within past 5 year except curatively treat carcinoma situ cervix basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior thalidomide No concurrent prophylactic filgrastim ( GCSF ) Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) No prior procarbazine No 2 prior chemotherapy regimen malignant glioma Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 3 month since prior radiotherapy Other Recovered prior therapy More 7 day since prior antidepressant ( selective serotonin reuptake inhibitor and/or monamine oxidase inhibitor ) No concurrent antidepressants No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>